{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:31:40Z","timestamp":1790357500547,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the potential for ethnicity\u2010related differences in ataluren pharmacokinetics (PK) and safety, a phase 1 single\u2010dose study was conducted in 48\u00a0healthy (24 Japanese and 24 Caucasian subjects), nonsmoking male volunteers who were equally divided into 3\u00a0cohorts of oral doses at 5, 10, and 20 mg\/kg. Blood samples were collected until 48 hours postdose. PK results demonstrated rapid absorption of ataluren, with peak plasma levels (C<jats:sub>max<\/jats:sub>) being attained between 0.875\u00a0and 2.5 hours after dosing. The mean C<jats:sub>max<\/jats:sub> and area under the concentration\u2010time curve (AUC<jats:sub>(0\u2010last)<\/jats:sub>) increased with each increasing dose level in both Japanese and Caucasian subjects. Although the C<jats:sub>max<\/jats:sub> was similar across all subjects at each dose regardless of ethnicity, Japanese subjects had a mean AUC<jats:sub>(0\u2010last)<\/jats:sub> approximately 14% to 34% lower than that of Caucasian subjects across the 3 dose levels. This difference was likely due to the higher variability of AUC values in Caucasian subjects and the relatively small study population. In conclusion, similar ataluren PK profiles were observed in healthy Japanese and Caucasian subjects following single oral administration of ataluren at all dose levels.<\/jats:p>","DOI":"10.1002\/cpdd.645","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T19:37:50Z","timestamp":1547149070000},"page":"172-178","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects"],"prefix":"10.1002","volume":"8","author":[{"given":"Ronald","family":"Kong","sequence":"first","affiliation":[{"name":"PTC Therapeutics, Inc  South Plainfield NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar L.","family":"Laskin","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc  South Plainfield NJ USA"},{"name":"R2D Pharma Services LLC  Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diksha","family":"Kaushik","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc  South Plainfield NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengbin","family":"Jin","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc  South Plainfield NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Ma","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc  South Plainfield NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc  South Plainfield NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Souza","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc  South Plainfield NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Almstead","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc  South Plainfield NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-120611-144851"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24332"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1909"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081302"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S93873"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70272-8"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.8.3710"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00248.2016"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2006.09.016"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00585-4"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23808"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21623"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22758"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20586"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31611-2"},{"key":"e_1_2_8_18_1","first-page":"37","article-title":"Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy","volume":"6","author":"Namgoong JH","year":"2016","journal-title":"Degener Neurol Neuromusc Dis"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006297140"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.141"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100482"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/js9702168"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645100-00001"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650100521"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.111"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050235"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198903023200905"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.182"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02368.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.155"},{"issue":"1","key":"e_1_2_8_31_1","first-page":"414","article-title":"Interindividual variations in human liver cytochrome P\u2010450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada T","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2073"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010381500"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-014-0083-6"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v4.i7.170"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.645","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T12:29:40Z","timestamp":1694694580000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1002\/cpdd.645"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.645","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"2017-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}